DOWNLOAD THIS SLIDE KIT

Design :

Endpoint :

• Primary endpoint: proportion of patients with HIV-1 RNA < 80 c/mLat W96 (ITT, missing equals failure analysis)
• Secondary endpoints: virologic failure (2 consecutive HIV-1 RNA> 500 c/mL), AIDS-defining illnesses, CD4, safety, adverse events

Baseline characteristics and patient disposition :

Virologic outcome :

Virologic outcome :

• 1 virologic failure (confirmed HIV-1 RNA > 500 c/mL) in each group. No resistance mutation on genotype
• No difference in CD4 changes between groups
• GI adverse events more frequent in the monotherapy group: 24 vs 10(p = 0.001)
• 5 patients in the triple therapy group underwent regimen changes due to drug-related toxicities